# Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

> **NCT00688688** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 2792 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** Mirabegron
- **DRUG:** Tolterodine
- **DRUG:** Placebo to Mirabegron
- **DRUG:** Placebo to Tolterodine

## Key facts

- **NCT ID:** NCT00688688
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-25
- **Primary completion:** 2010-05-06
- **Final completion:** 2010-05-06
- **Target enrollment:** 2792 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00688688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00688688, "Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00688688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*